The landscape of bispecific T cell engager in cancer treatment
Abstract T cell-based immunotherapies have revolutionized treatment paradigms in various cancers, however, limited response rates secondary to lack of significant T-cell infiltration in the tumor site remain a major problem. To address this limitation, strategies for redirecting T cells to treat can...
Main Authors: | Shujie Zhou, Mingguo Liu, Fei Ren, Xiangjiao Meng, Jinming Yu |
---|---|
Format: | Article |
Language: | English |
Published: |
BMC
2021-05-01
|
Series: | Biomarker Research |
Subjects: | |
Online Access: | https://doi.org/10.1186/s40364-021-00294-9 |
Similar Items
-
Bispecific T cell engagers: an emerging therapy for management of hematologic malignancies
by: Zheng Tian, et al.
Published: (2021-05-01) -
Therapeutic Bispecific T-Cell Engager Antibody Targeting the Transferrin Receptor
by: Mingpeng Fu, et al.
Published: (2019-06-01) -
Bispecific Antibodies: A Smart Arsenal for Cancer Immunotherapies
by: Gihoon You, et al.
Published: (2021-07-01) -
Oncolytic viruses encoding bispecific T cell engagers: a blueprint for emerging immunovirotherapies
by: Johannes P. W. Heidbuechel, et al.
Published: (2021-04-01) -
Research and Clinical Landscape of Bispecific Antibodies for the Treatment of Solid Malignancies
by: Gabriele Antonarelli, et al.
Published: (2021-08-01)